Judith Trotman Selected Research

zanubrutinib

1/2022	Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
1/2022	Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.
1/2022	Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies.
12/2021	The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.
1/2021	Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma.
12/2020	Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.
10/2020	A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
10/2020	Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up.
12/2019	Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
1/2018	Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström macroglobulinemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Judith Trotman Research Topics

Disease

20	Neoplasms (Cancer) 01/2022 - 09/2010
16	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 05/2022 - 08/2011
9	Waldenstrom Macroglobulinemia (Macroglobulinemia) 05/2022 - 01/2018
9	Lymphoma (Lymphomas) 05/2022 - 09/2010
5	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2022 - 01/2017
5	Atrial Fibrillation 01/2022 - 06/2018
5	B-Cell Lymphoma (Lymphoma, B Cell) 11/2021 - 08/2011
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022 - 09/2010
4	Hodgkin Disease (Hodgkin's Disease) 01/2021 - 05/2015
4	Infections 01/2021 - 01/2017
4	Neutropenia 10/2020 - 01/2017
3	Diarrhea 01/2022 - 06/2018
3	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2022 - 10/2019
3	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2022 - 01/2019
3	Hypertension (High Blood Pressure) 01/2022 - 06/2018
2	Pneumonia (Pneumonitis) 01/2022 - 10/2020
2	Peripheral Nervous System Diseases (PNS Diseases) 12/2021 - 01/2017
2	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 12/2021 - 01/2017
2	Mycosis Fungoides 12/2021 - 01/2021
2	Edema (Dropsy) 01/2021 - 10/2020
2	COVID-19 01/2021 - 01/2020
2	Hemorrhage 12/2020 - 10/2020
2	Anemia 10/2019 - 02/2017
2	Multiple Myeloma 01/2017 - 05/2010
1	Sepsis (Septicemia) 01/2022
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022
1	Inflammation (Inflammations) 01/2022
1	Fever (Fevers) 01/2022
1	Disease Progression 01/2022
1	Pruritus (Itching) 12/2021
1	Primary Cutaneous Anaplastic Large Cell Lymphoma 12/2021
1	Pain (Aches) 12/2021
1	T-Cell Lymphoma (Lymphoma, T Cell) 01/2021
1	Spasm (Spasms) 10/2020
1	Contusions 10/2020
1	Fatigue 01/2020
1	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 01/2019
1	Second Primary Neoplasms (Neoplasms, Second) 10/2018
1	Arthralgia (Joint Pain) 06/2018
1	Nausea 06/2018
1	Hemolysis 01/2018
1	Transfusion Reaction 01/2018
1	Venous Thromboembolism 01/2017
1	Mucositis 01/2016
1	Stomatitis 01/2016
1	Crohn Disease (Crohn's Disease) 05/2015

Drug/Important Bio-Agent (IBA)

14	Rituximab (Mabthera)FDA Link 01/2022 - 10/2014
10	Agammaglobulinaemia Tyrosine KinaseIBA 05/2022 - 10/2018
10	zanubrutinibIBA 01/2022 - 01/2018
10	ibrutinibIBA 01/2022 - 06/2018
6	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2022 - 09/2010
6	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019 - 06/2016
5	GalliumIBA 01/2022 - 10/2018
5	obinutuzumabIBA 01/2020 - 10/2018
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019 - 01/2017
4	Lenalidomide (CC 5013)FDA Link 01/2022 - 01/2017
4	Bendamustine Hydrochloride FDA Link 01/2022 - 10/2018
4	Prednisone (Sone)FDA LinkGeneric 01/2019 - 01/2017
4	Vincristine (Oncovin)FDA LinkGeneric 01/2019 - 08/2017
3	Brentuximab VedotinIBA 12/2021 - 01/2017
3	Melphalan (Alkeran)FDA LinkGeneric 01/2017 - 05/2010
2	Histone Deacetylase InhibitorsIBA 01/2022 - 10/2020
2	Methotrexate (Mexate)FDA LinkGeneric 12/2021 - 05/2015
2	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2018
2	Prednisolone (Predate)FDA LinkGeneric 01/2019 - 05/2015
2	Immunoglobulin M (IgM)IBA 06/2018 - 01/2017
1	BNT162 VaccineIBA 05/2022
1	Immunoglobulin G (IgG)IBA 05/2022
1	AntigensIBA 05/2022
1	romidepsin (FK228)FDA Link 01/2022
1	Biological ProductsIBA 01/2022
1	tafasitamabIBA 01/2022
1	Bexarotene (LGD1069)FDA Link 12/2021
1	10-propargyl-10-deazaaminopterin FDA Link 01/2021
1	COVID-19 VaccinesIBA 01/2021
1	Enoxaparin (Lovenox)FDA LinkGeneric 12/2020
1	MLN 8237IBA 10/2019
1	Aurora Kinase AIBA 10/2019
1	Pharmaceutical PreparationsIBA 05/2019
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2019
1	Proton Pump InhibitorsIBA 01/2019
1	Ifosfamide FDA LinkGeneric 01/2017
1	IceIBA 01/2017
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2017
1	Carboplatin (JM8)FDA LinkGeneric 01/2017
1	ParaproteinsIBA 01/2017
1	Etoposide (VP 16)FDA LinkGeneric 01/2017
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2017
1	Carmustine (FIVB)FDA Link 01/2017
1	ibritumomab tiuxetan (Zevalin)FDA Link 01/2017
1	Bleomycin (Blenoxane)FDA LinkGeneric 06/2016
1	Dacarbazine (DIC)FDA LinkGeneric 06/2016
1	Vinblastine (Vinblastine Sulfate)FDA Link 06/2016
1	Infliximab (Remicade)FDA Link 05/2015

Therapy/Procedure

24	Therapeutics 01/2022 - 05/2010
5	Drug Therapy (Chemotherapy) 01/2020 - 10/2014
3	Induction Chemotherapy 01/2021 - 01/2020
1	Drug Tapering 01/2022
1	Aftercare (After-Treatment) 01/2018
1	Stem Cell Transplantation 01/2017